NEW YORK (GenomeWeb) – Danaher today reported an 11 percent year-over-year increase in its fourth quarter revenues, with its Life Sciences and Diagnostics segments growing above the companywide rate.

Danaher also announced a transition plan for Daniel Comas, who will step down as CFO on Jan. 1, 2019, to be replaced by Matthew McGrew.

For the three months ended Dec. 31, 2017, total revenues came in at $5.09 billion, up from $4.58 billion in the year-ago period, and beating the consensus Wall Street estimate of $4.98 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.